Chemo through liver artery with lipiodol for advanced liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests giving chemotherapy directly into the liver artery (HAIC) mixed with a special oil called lipiodol. It may help people with advanced liver cancer that cannot be treated with standard methods or who cannot tolerate them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have liver cancer (HCC) that has spread within the liver or to nearby areas, or has come back after other treatments
- You are over 20 years old and weigh more than 66 pounds (30 kg)
- You are generally active and able to care for yourself (ECOG 0 or 1)
- Your liver function is good (Child-Pugh class A or up to B7) and your blood counts and kidney function meet specific levels
- If you are a woman who could become pregnant, you must have a negative pregnancy test; all people must use effective birth control during and 90 days after treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies HAIC, a type of targeted treatment delivered into the liver, for advanced hepatocellular carcinoma (liver cancer) that has already been treated with immune and anti-blood-vessel therapies. It aims to see whether HAIC can help control the cancer safely after those earlier treatments.
This trial tests a combination of two drugs (lenvatinib and toripalimab, a type of immunotherapy) plus a special chemotherapy infusion directly into the liver artery for people with advanced liver cancer that has not been treated before. The goal is to see if adding the immunotherapy helps shrink tumors better than the standard combination.
This trial tests adding a targeted chemo infusion into the liver's main artery to two immunotherapy drugs for liver cancer. It may help patients whose cancer has spread within the liver and can't be removed by surgery.
This trial tests a combination of three treatments for advanced liver cancer (BCLC stage C): HAIC (chemotherapy directly into the liver), adebrelimab (immunotherapy that helps your immune system fight cancer), and apatinib (a targeted drug that cuts off blood supply to tumors). It may be an option if you have not had any prior systemic (whole-body) therapy for liver cancer.
This trial tests a combination of three treatments for advanced liver cancer that can't be removed by surgery. It uses an immunotherapy drug (cadonilimab), a targeted therapy pill (lenvatinib), and a direct chemotherapy infusion into the liver (HAIC). The goal is to see if this combo can shrink tumors and improve outcomes.
This trial tests a special type of chemotherapy (hepatic artery infusion) for people with cancers that have spread to the liver, such as colorectal cancer or bile duct cancer (intrahepatic cholangiocarcinoma). It studies whether delivering this treatment partly at a community center and partly at a university hospital is safe and feasible.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.